Today: 19 May 2026
Lam Research stock price slides 6% into the weekend — here’s what LRCX investors watch next
31 January 2026
2 mins read

Lam Research stock price slides 6% into the weekend — here’s what LRCX investors watch next

NEW YORK, Jan 31, 2026, 05:42 EST — Market closed

Lam Research Corporation shares (LRCX.O) closed Friday down 5.9%, settling at $233.46. The stock fluctuated between a high near $251.90 and a low around $232.28 during the session. With U.S. markets closed over the weekend, the next price action will depend largely on how investors interpret the company’s outlook and risk disclosures ahead of Monday’s open.

This shift is crucial since Lam serves as a bellwether for wafer fabrication equipment (WFE) — the expensive machinery essential for producing chip wafers. Its guidance often recalibrates forecasts for chip investments linked to AI servers and cutting-edge memory. The market has shown little tolerance for anything less than faster growth in this space.

The broader market also retreated Friday, with the Nasdaq sliding 0.94% as investors digested Donald Trump’s choice of Kevin Warsh to replace Jerome Powell at the Fed, along with new inflation figures. “Markets are calibrating” to Warsh’s nomination, noted Michael Hans of Citizens Wealth. Chip-equipment maker KLA Corp plunged 15.2% on the session. Reuters

Lam reported December-quarter revenue of $5.34 billion and adjusted earnings of $1.27 a share in an 8-K filing dated Jan. 28. Looking ahead to the quarter ending March 29, the company forecast revenue around $5.70 billion, with a $300 million margin either way, adjusted earnings near $1.35 a share, plus or minus 10 cents, and a gross margin close to 49%, give or take one percentage point. “Lam delivered another strong quarter to cap a record year,” CEO Tim Archer said. China accounted for 35% of revenue in the quarter. app.quotemedia.com

LSEG data in a separate report pegged Wall Street’s estimate for Lam’s March-quarter revenue at $5.34 billion, with adjusted earnings of $1.20 per share—both shy of Lam’s midpoint guidance. The report also highlighted Lam’s memory segment as a possible upside, driven by rising demand for high-bandwidth memory—the stacked, high-speed chips powering AI accelerators.

A quarterly report filed on Jan. 29 highlighted the downside. The 10-Q cautioned that tariffs and export controls — including tougher U.S. export-license rules impacting sales connected to China — have constrained some business and could further shrink the market for its tools. At the same time, these rules may give an edge to competitors not subject to the same restrictions.

The peer read-through has been messy. KLA topped estimates, yet its shares fell in after-hours trading. “The problem is that the stock had already sprinted into the print,” said Michael Ashley Schulman of Running Point Capital Advisors. Reuters

Lam now faces the question of whether strong demand will continue to drive orders and if services revenue can cushion any dips in new-tool shipments. Friday’s slide in the stock indicates investors remain uncertain about how much of the positive outlook is already reflected in the price.

Shares of peers like Applied Materials and ASML often influence Lam on a daily basis, particularly during risk-off swings. That connection has grown stronger recently—and not always for the better.

Next week kicks off with a busy earnings calendar and the U.S. jobs report, both likely to influence high-multiple tech stocks early on. Key data points arrive quickly: the ISM manufacturing PMI, a closely watched gauge of factory activity, is set for 10:00 a.m. EST Monday, Feb. 2. Then on Friday, Feb. 6 at 8:30 a.m. ET, the Labor Department releases its January employment report.

Stock Market Today

  • Asian Shares Mixed; Kospi Drops 3% Amid Volatile Oil Prices
    May 19, 2026, 4:28 AM EDT. Asian stock markets showed mixed performances on Tuesday, with South Korea's Kospi index tumbling 3%. The sell-off was driven by ongoing volatility in oil prices, which continue to sway investor sentiment. Analysts noted that fluctuations in crude oil markets are impacting broader market stability, contributing to cautious trading across Asia. The Kospi's decline reflects concerns over energy costs and their potential impact on corporate earnings and economic growth in the region. Meanwhile, other Asian markets saw varied movements as investors balanced risks amid uncertain commodity trends.

Latest articles

T1 Energy Stock Just Popped 23%. The Filing Behind the Move Is the Story

T1 Energy Stock Just Popped 23%. The Filing Behind the Move Is the Story

19 May 2026
T1 Energy Inc. shares surged 23.46% to $7.00 Monday after a regulatory filing revealed Situational Awareness LP held 10 million shares, valued at $43.9 million as of March 31. Trading volume hit 88 million shares, far above the 20-day average. T1 reported Q1 net sales of $177.6 million and a net loss to common stockholders of $21.4 million. Construction at its G2_Austin solar site remains on schedule.
HIVE Stock Up 29% While Nasdaq Moves Lower as Traders Eye AI Gigafactory

HIVE Stock Up 29% While Nasdaq Moves Lower as Traders Eye AI Gigafactory

19 May 2026
HIVE Digital Technologies closed at $3.46 on Nasdaq Monday, up 28.6%, and rose to $3.59 after hours following news of a planned 320 MW AI data center near Toronto targeting over 100,000 GPUs. The project is expected to cost C$3.5 billion and open in late 2027. Shares of other crypto miners fell as bitcoin traded near $77,142.
Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

19 May 2026
Ameren shareholders approved executive pay, re-elected the full board, and ratified PwC as auditor. CEO Martin J. Lyons, Jr.’s 2025 compensation rose to $14.06 million, up from $9.73 million the previous year. The “say-on-pay” proposal received over 208 million votes in favor. Ameren shares last traded at $107.38, up $1.02.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Shopify stock slides nearly 9% as Fed-chair jitters build ahead of Feb. 11 earnings
Previous Story

Shopify stock slides nearly 9% as Fed-chair jitters build ahead of Feb. 11 earnings

First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut
Next Story

First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut

Go toTop